HRD TESTING
EXPLAINED
HRD testing identifies the DNA repair deficiency that makes certain cancers vulnerable to PARP inhibitors -- and captures a broader population than BRCA testing alone. HRD is not just BRCA testing under a different name.
PARP Inhibitor Approvals by Cancer Type and HRD Status
| Cancer Type | HRD Requirement | Approved Agents |
|---|---|---|
| High-grade serous ovarian cancer | BRCA-mutated: strongest benefit; HRD-positive (non-BRCA): meaningful benefit; HRD-negative: limited benefit | Olaparib, niraparib, rucaparib (multiple approvals) |
| HER2-negative metastatic breast cancer | Germline BRCA mutation required | Olaparib, talazoparib |
| Metastatic castration-resistant prostate cancer | BRCA-mutated or HRD-positive | Olaparib, rucaparib, niraparib |
| Metastatic pancreatic cancer | BRCA-mutated (maintenance after platinum) | Olaparib |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About HRD Testing and PARP Inhibitor Eligibility?
CancerFax reviews your BRCA and HRD status to assess PARP inhibitor eligibility across ovarian, breast, prostate, and pancreatic cancer indications.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.